Peterson Wealth Services Acquires 6,479 Shares of Lantheus Holdings, Inc. $LNTH

Peterson Wealth Services increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3,160.5% during the first quarter, according to its most recent filing with the SEC. The fund owned 6,684 shares of the medical equipment provider’s stock after buying an additional 6,479 shares during the quarter. Peterson Wealth Services’ holdings in Lantheus were worth $507,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Abel Hall LLC boosted its stake in Lantheus by 4.6% in the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after acquiring an additional 172 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 230 shares during the period. Vident Advisory LLC raised its holdings in shares of Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after purchasing an additional 230 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Down 0.7%

Lantheus stock opened at $105.99 on Friday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.86. The firm has a market capitalization of $6.90 billion, a price-to-earnings ratio of 25.54 and a beta of -0.06. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The firm has a 50 day simple moving average of $100.22 and a 200 day simple moving average of $82.74.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same quarter in the previous year, the firm posted $1.53 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, analysts predict that Lantheus Holdings, Inc. will post 4.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on LNTH shares. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Finally, Mizuho boosted their price objective on Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.29.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.